Cerevance Is A Clinical Stage Biopharmaceutical Company Focused On Discovering And Developing New Therapeutics For Neurological And Psychiatric Disordersfounded In 2016The Company Operates From Headquarters In Osakajapanand Cambridgemait Has Received Substantial Fundingincluding A $21 5 Million Series A Financing And A Subsequent $20 Million In Series B Financingprimarily From Takeda Pharmaceutical Company Limited And Lightstone Ventures The Company Utilizes A Proprietary Technology Platform Called Netsseqwhich Analyzes Gene Expression Profiles In Specific Brain Cell Typesthis Platformdeveloped At Rockefeller Universityenables Cerevance To Identify Molecular Changes Linked To Neurological Disorders And Discover New Drug Targetstheir Pipeline Includes Both Preclinical And Clinical Stage Drug Programs Aimed At Treating Neurodegenerative And Psychiatric Conditionssupported By Advanced Machine Learning Techniquescerevance Collaborates With Major Pharmaceutical Partnersenhancing Its Capabilities In The Healthcare Sector
